A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis

Sponsor
University of Aarhus (Other)
Overall Status
Completed
CT.gov ID
NCT02157155
Collaborator
(none)
9
1
2
15
0.6

Study Details

Study Description

Brief Summary

Hypothesis

  1. To define whether stimulation of ATGL and suppression of G0/G1 switch gene occur in the initial phases of diabetic ketoacidosis and thus can be identified as the primary mechanisms behind this life threatening condition.

  2. Make a human model for studying ketoacidosis.

The investigators plan to reduce in their regular insulin over night. In the morning we administer endotoxin, which together with a relative lack of insulin will initiate ketogenesis - a state of ketoacidosis. On another occasion strict glycemic control is imposed by means of intravenous insulin. The testing is done two separate days with at least 3 weeks in between and patients are admitted to hospital the evening before the day of testing. The investigators use isotopic tracers to determine metabolic fluxes and analyse fat (ATGL, G0/G1 switch gene) and muscle biopsies.

Condition or Disease Intervention/Treatment Phase
  • Biological: LPS
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
9 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
The Role of ATGL and G0/G1 Switch Gene Complex in Lipopolysaccaride (LPS) Induced Ketosis - a Controlled, Randomised, Clinical Experimental Study
Study Start Date :
Jun 1, 2014
Actual Primary Completion Date :
Mar 1, 2015
Actual Study Completion Date :
Sep 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Insulin reduction and mimic infection with LPS

Biological: LPS
LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.

No Intervention: Control

Normal insulin and no LPS

Outcome Measures

Primary Outcome Measures

  1. Insulin signaling expressed as a CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue. [Muscle and fat biopsies obtained on each study day (arm): t1= 6.45 (-75min) am t2=11.15 (195min) am t3= 12.30 pm (270min)]

    Change in phosphorylation of target proteins and messenger RNA (mRNA) expression of target genes assessed with western blotting technique.

Secondary Outcome Measures

  1. Change in Intracellular markers of lipid metabolism in muscle- and fat tissue biopsies [Muscle and fat biopsies obtained on each study day (arm): t1= 6.45 am (-75min) t2=11.15 (195min) am t3= 12.30 pm (270min)]

    Muscle and fat at t1 and t2. Muscle biopsy at t3. Intracellular markers are assessed by western blotting.

  2. Metabolism [Change in glucose, fat and protein metabolism between study days and during each study day]

    Change in glucose, fat and protein metabolism assessed by tracer kinetics on every study day (specific times below) and by indirect calorimetry. [3H 3]Glucose tracer from t=0 - 360min. Palmitic acid tracer from t=165min - 360min. Urea tracer from 0min - 240min. amino acid tracer from 60 min - 360 min.

  3. Cytokines and stress hormones [In basal period t=0-240 minutes and in clamp period t=240-390 minutes]

    Measurement of immune response to endotoxin and hypoinsulinaemia. Estimating the whole body stress during ketoacidosis and pre ketoacidosis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diabetes type 1

  • 19 < BMI < 26

  • minimal or negative C-peptide

  • written consent

Exclusion Criteria:
  • Severe comorbidity

  • regular medication apart from insulin

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aarhus University Hospital Aarhus Denmark 8000

Sponsors and Collaborators

  • University of Aarhus

Investigators

  • Principal Investigator: Mads Svart, MD, Aarhus University / Aarhus University Hospital
  • Study Chair: Niels Møller, MD, Aarhus University / Aarhus University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT02157155
Other Study ID Numbers:
  • 1-10-72-98-14
First Posted:
Jun 5, 2014
Last Update Posted:
Dec 2, 2015
Last Verified:
Jun 1, 2014
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 2, 2015